Gesche Tallen

Associate Member

ACHRI

Adjunct Associate Professor

Paediatrics

Master Teacher

CSM UME

MD (Doctor of Medicine)

PhD (Doctor of Philosophy)


Contact information

Office hours

ACH Oncology 2nd floor


Research

Areas

  • Cancer
  • Genomics
  • Parmacotherapy
  • Knowledge Translation
  • Quality Improvement
  • Child Welfare

Research Summary

Title of Study: Implementation of a Pharmacogenomic Adverse Drug Reaction (ADR) Prevention Program at Alberta Children’s Hospital

The purpose of this study is to implement a genetic testing program at Alberta Children’s Hospital for children receiving cisplatin, anthracycline, and/or thiopurine chemotherapy, and to determine the utility of this program in preventing adverse reactions to these drugs.

Specific goals of the study are:
(1) Provide doctors who treat children with cancer with the clinical practice guidelines developed for genetic testing to determine a child’s risk of cisplatin-induced hearing loss, anthracycline-induced heart problems, and thiopurine-induced bone marrow suppression (decrease in blood cells).
(2) Provide results of this genetic testing to the doctors caring for patients in this study, as well as to the patients/families.
(3) Determine the usefulness of the genetic testing to doctors and patients and families

Rationale: The identification and development of predictive genetic markers will ultimately help to reduce anthracycline-induced cardiotoxicity, thiopurine-induced immunosuppression and cisplatin-induced ototoxicity, thereby improving the safety of cancer therapy and reducing late effects.